In HER2-positive early breast cancer, patients treated with HER2 inhibitor had exciting survival rates which exceeded 90%; Similarly, in lung cancer, the ORR of EGFR inhibitor treatment in patients harboring EGFR mutation reaches 75% [30], all of which suggested that targeted therapies have a growing prominence in cancer patient management and drug development. This evidence concerns the gene EGFR and cancer.